Antiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes: KeyRecommendations JACC . 2025 Jun, 85 (22) 2074–2078 The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for theManagement of Patients With Acute Coronary Syndromes (ACS), published in this issue of JACC, replaces the prior U.S. guidelines on the management of ST-segment and non–ST-segment elevation ACS. The new guideline provides anexcellent evidence-based framework for diagnosis and management of type I...
Jun 30, 2025•4 min
The 2025 Guideline for the Management of Patients With Acute Coronary Syndromes: Asian Perspective https://www.jacc.org/doi/full/10.1016/j.jacc.2025.04.011 The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for theManagement of Patients with Acute Coronary Syndromes introduces key updates that may influence global clinical practice. Given Asia’s immense population and regional diversity, assessing how these U.S.-based guidelines translate into real-world application is essential.Although grounded in ro...
Jun 30, 2025•5 min
Exploring the Impact of Beta-Blockers Post-Acute Myocardial Infarction in Patients with Preserved Ejection Fraction: A Meta-Analysis J. Clin. Med. 2025, 14 (11), 3969; https://doi.org/10.3390/jcm14113969 Abstract Background/Objectives: Previous research has establishedthat beta-blockers significantly reduce all-cause mortality, cardiovascular mortality, and recurrent acute myocardial infarction (AMI) in patients with left ventricular dysfunction following AMI. However, their efficacy in patients...
Jun 30, 2025•3 min
Pragmatic Use of Ticagrelor: ImprovingOutcomes in Medical Management of Acute Coronary Syndrome (PracTiCal India Study) Journal of Indian College of Cardiology ():10.4103/jicc.jicc_73_24, June 05, 2025. | DOI: 10.4103/jicc.jicc_73_24 Abstract Background: The utilization of ticagrelor in the medical management ofacute coronary syndrome (ACS) has been extensively explored in interventions such as percutaneous coronary intervention. However, its use in acute coronarysyndrome without intervention re...
Jun 30, 2025•3 min
Effect of Body Mass Index in Patients With Cardiogenic Shock Requiring Microaxial Flow Pump JACC: Asia . May 04, 2025. Epublished DOI:10.1016/j.jacasi.2025.03.003 Abstract Background The impact of obesity on mortality in patients with cardiogenic shock (CS) requiring microaxial flow pumps (mAFP) remains undetermined. Objectives This study investigated the effect of body mass index (BMI) on mortality in CS patients treated with microaxial flow pumps Methods Data from 3,636 consecutive CS patients...
May 31, 2025•3 min
The Impact of Preoperative P2Y12 Inhibitors on Short- and Long-Term Outcomes Following Percutaneous CoronaryIntervention DOI: 10.1016/j.jscai.2025.103226 ExternalLink Background The preoperative usage of P2Y12 inhibitors primarily aim to reduce thrombotic complications for percutaneous coronary intervention (PCI), however, there is limited data on how these medications impact rates of adverse outcomes post- percutaneous coronary intervention. Methods We conducted a single-center observationalstu...
May 31, 2025•3 min
Incidence and Risk Factors of De Novo Postpartum Hypertension: Understanding Links to Long-Term Cardiovascular Risk JACC Adv . 2025 Jun, 4 (6_Part_1) 101756 Abstract Background Individuals developing hypertensive disorders of pregnancy face a 2- to 5-fold risk of long-term cardiovascular disease. Limited data exist on de novo postpartum hypertension (dnPPHTN), where those normotensive during pregnancy develop hypertension immediately postpartum.Under-recognition of de novo postpartum hypertensio...
May 31, 2025•3 min
Aspirin vs Clopidogrel vs Ticagrelor Monotherapy Compared to 12 Months of DAPT Following PCI; A Systematic Review and Meta-Analysis DOI: 10.1016/j.jscai.2025.103158 ExternalLink Background Short-term Dual Antiplatelet Therapy (DAPT) may reduce the risk of bleeding after Percutaneous Coronary Intervention (PCI) as compared to the standard 12 months of Dual Antiplatelet Therapy . However, it may not provide the same benefits against stent thrombosis and ischemic events. We aim to analyse the vario...
May 31, 2025•3 min
Does Timing of Coronary Artery Bypass Grafting after ST-Elevation Myocardial Infarction Impact Early- and Long-Term Outcomes? DOI: 10.1055/s-0044-1787851 Abstract Background: The optimal timing of surgicalrevascularization after ST-elevation myocardial infarction (STEMI) is controversial, with some suggesting higher mortality rates in patients undergoing early surgery. The aim of the study is to determine the effect of the timing of surgical revascularization on 30-day mortality and long-termout...
May 01, 2025•3 min
Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a DayClopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention DOI: 10.1016/j.ahj.2025.03.021 Abstract Background: Ticagrelor has been proven superior toclopidogrel in reducing adverse cardiovascular events in patients with acute coronary syndrome (ACS), yet economic factors often favor clopidogrel in real-world...
May 01, 2025•3 min
In-hospital use of beta-blockers for critically ill patients with acute heart failure: Whether and when to initiate DOI: 10.1016/j.jclinane.2025.111824 Abstract Background: The use of beta-blockers during hospitalization for acute heart failure (AHF) remains controversial. This study aimed to investigate whether beta-blocker use isassociated with a reduced risk of mortality in critically ill patients with AHF and to determine the optimal timing for initiating beta-blocker therapy. Methods : Data...
May 01, 2025•3 min
1. Dual antiplatelet therapy is recommended for patients with acute coronary syndromes (ACS). Ticagrelor or prasugrel is recommended in preference to clopidogrel in patients with ACS who are undergoing percutaneous coronary intervention (PCI). In patients with non–ST-segment elevation ACS who are scheduled for an invasive strategy with timing of angiography to be >24 hours, upstream treatment with clopidogrel or ticagrelor may be considered to reduce major adverse cardiovascular events. 2. Du...
May 01, 2025•6 min
Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure withreduced ejection fraction https://link.springer.com/article/10.1186/s43044-025-00629-z Heart failure (HF) is a significant global health issue. Appropriate and timely treatment at target doses significantly reduces mortality and enhances quality of life. However, studies indicate suboptimal pharmacotherapy among patients. This study aims to assess the medical treatment of patients with...
Mar 31, 2025•4 min
Early β-Blocker Use and Clinical Outcomes in Acute Myocardial Injury: A Retrospective Cohort Study https://doi.org/10.1016/j.amjmed.2025.02.029 Abstract Background Acute myocardial injury is defined by elevated cardiactroponin (cTn) levels with a rising and/or falling pattern, and is associated with increased mortality risk compared to patients without myocardial injury. The role of β-blockers in patients with acute myocardial injury remains unclear. Methods This multicenter, retrospective cohor...
Mar 31, 2025•3 min
Impact of Metabolic Syndrome on Clinical Profile and Prognosis in Patients with Acute ST-Elevation MyocardialInfarction: a Cross-Sectional Study https://link.springer.com/article/10.1007/s42399-025-01822-6 Abstract Metabolic syndrome (MS) has gained attention as a newly discovered risk factor for coronary artery disease (CAD).Studies have demonstrated that individuals with MS have a higher risk for coronary artery disease (CAD), and the risk is higher in females compared to males. Patients with ...
Mar 31, 2025•3 min
The “Silent Enemy” Called Renal Artery Stenosis: A Mini-Review: J. Vasc. Dis. 2025, 4(1), 10; https://doi.org/10.3390/jvd4010010 Renal artery stenosis (RAS) is a vascular condition characterized by narrowing of one or both renal arteries, leading to reduced blood flow to the kidneys, activation of the renin–angiotensin–aldosterone system (RAAS), and subsequent renovascular hypertension. Overactivation of the same cascade potentiates the production of angiotensin II, which induces systemic vasoco...
Mar 31, 2025•4 min
Impact of controlled stepwise reperfusion during primary percutaneous coronary intervention on patients with ST-elevation myocardial infarction Abstract Objective: The aim of this study is to examine the impact of controlled stepwise reperfusion by modulating pre-dilation balloonpressure during primary percutaneous coronary interventions (PPCI) in patients with ST-elevation myocardial infarction (STEMI). Methods: Consecutive ST-elevation myocardial infarction patients requiring primary percutane...
Feb 28, 2025•3 min
The use of beta-blockers for heart failure with reduced ejection fraction in the era of SGLT2 inhibitors – are westill afraid to up-titrate? DOI https://doi.org/10.1007/s00380-025-02525-7 Beta-blockers are one of the four major pillars of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). The therapy has presented the best effects when up-titrated to evidence-based target doses. Despite their proven benefits, physicians have traditionally shown re...
Feb 28, 2025•4 min
Triglyceride glucose-waist circumference as a predictor of mortality and subtypes of cardiovascular disease: asystematic review and meta-analysis DOI https://doi.org/10.1186/s13098-025-01616-9 Abstract Background The significant burden of cardiovascular diseases underscores the necessity for identifying novel predictive markers that can forecast both cardiovascular diseases and mortality. In recent years, Triglycerideglucose -obesity-related parameters have gained special attention in thisregard...
Feb 28, 2025•3 min
De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systemic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials Ann Intern Med . 2025 Feb 18. doi: 10.7326/ANNALS-24-03102. Abstract Background: The role of transitioning from shortdual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES)implantation remains inconclusive. Purpose: T...
Feb 28, 2025•4 min
Impact of beta-blocker up titration on patients after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation: The OCEAN-mitral registry https://doi.org/10.1016/j.ijcard.2024.132595 Abstract Background Optimal medical therapy for patients with secondary mitral regurgitation (SMR) undergoing transcatheter edge-to-edge mitral valve repair (M-TEER) remains unclear. This study aimed to investigate the association between beta-blocker up titration and clinical outcomes after...
Jan 31, 2025•3 min
Examining the Specificity of Smartphone ECG Devices in Decision-Making for ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction DOI: https://doi.org/10.30701/ijc.1740 Abstract Background & Objectives: Electrocardiography (ECG) stands as a cornerstone diagnostic tool for assessing cardiac health, particularly in ruling out abnormalities. The integration of smartphone devices presents a promising avenue for expedited detection of cardiac irregularities. This study aims...
Jan 31, 2025•3 min
Metoprolol vs diltiazem for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis of adverse events https://doi.org/10.1016/j.ajem.2024.12.070 Abstract Background Intravenous (IV) diltiazem and metoprolol are commonly used to achieve rate control for atrial fibrillation with rapid ventricular rate (Afib with RVR), and are both recommended as first-line by current guidelines. While prior studies investigated the efficacy of these medications, there is little evidenc...
Jan 31, 2025•3 min
TICA-CLOP STUDY: Ticagrelor Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke, a Randomized Controlled Multi-Center Trial Randomized Controlled Trial CNS Drugs. 2025 Jan;39(1):81-93. doi: 10.1007/s40263-024-01127-7. Abstract Background: Many studies evaluated the efficacy and safety of ticagrelor versus clopidogrel in patients with ischemic stroke; none of these trials included North African participants, and all of these trials comprised only participants who experienc...
Jan 31, 2025•3 min
Impact of Adherence to Beta-Blockers in Patients With All-Comers ST-Segment Elevation Myocardial Infarction and According to Left Ventricular Ejection Fraction at Discharge: Results From the Real-World Registry FAST-STEMI J Cardiovasc Pharmacol . 2024 Dec 1;84(6):581-589. doi: 10.1097/FJC.0000000000001627. Abstract Beta-blockers are a crucial part of post-myocardial infarction (MI) pharmacological therapy. Recent studies have raised questions about their efficacy in patients without reduced left...
Dec 31, 2024•4 min
Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure JAMA Cardiol . 2024 Dec 1;9(12):1154-1158. doi: 10.1001/jamacardio.2024.3023. Abstract Importance: Guideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. Objective ...
Dec 31, 2024•3 min
A comparison of the effects of ticagrelor and clopidogrel in patients with acute ST-segment elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials BMC Pharmacol Toxicol. 2024 Dec 9;25(1):93. doi: 10.1186/s40360-024-00817-8. Abstract Background: Rupture of unstable coronary atherosclerotic plaque leads to acute ST-segment elevation myocardial infarction (STEMI). Dual anti-platelet therapy is one of the main treatments, and the combination of Aspirin a...
Dec 31, 2024•3 min
Intravascular imaging-guided percutaneous coronary intervention in patients with acute myocardial infarction and cardiogenic shock Rev Esp Cardiol (Engl Ed) . 2024 Dec;77(12):995-1007. Abstract Introduction and objectives : There are no clinical data on the efficacy of intravascular imaging-guided percutaneous coronary intervention (PCI) compared with angiography-guided percutaneous coronary intervention in patients with acute myocardial infarction (AMI) and cardiogenic shock. The current study ...
Dec 31, 2024•3 min
Guideline-directed medical therapy improves cell viability in an iPSC-derived cardiomyocyte hypoxia injury model https://doi.org/10.1161/circ.150.suppl_1.4147229 Abstract Introduction: Beta blockers, renin-angiotensin-aldosterone antagonists, and mineralocorticoid antagonists are mainstays of current guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction. They have been shown to reduce morbidity and mortality in heart failure patients, reverse remodeling, and i...
Nov 30, 2024•4 min
Ticagrelor monotherapy the way forward after Percutaneous Coronary Interventions: An updated meta-analysis https://doi.org/10.1161/circ.150.suppl_1.4124335 Abstract Background: With the advent of newer generation drug eluting stents, the chorus for shortening the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary interventions (PCI) is getting louder and louder. Ticagrelor monotherapy after a short course of dual antiplatelet therapy has been studied in a few randomized con...
Nov 30, 2024•3 min
